2011
DOI: 10.4028/www.scientific.net/amr.236-238.2378
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of Novel Drug Benvitimod

Abstract: Benvitimod (3,5-dihydroxy-4-i-propylstilbene) is a novel drug developed for common skin disorders such as atopic dermatitis by Welichem Biotech Inc. in Canada and Celestial Pharmaceuticals (Shenzhen) Co. Ltd. in China. But the ideal synthesis method is not reported so far. Herein an efficient synthesis method which is operated under the mild conditions is reported. According this route, the total yield will reach 40.3 - 48.1% and the benefits of the improved method are easily operating and environment friendly. Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 10 publications
0
3
0
Order By: Relevance
“…101,102 It was first developed under the name WBI-1001 by Welichem Biotech Inc. in China. 103 Benvitimod 1% (Beijing Wenfeng Tianji Pharma Ltd.) uses a petrolatum-based vehicle for delivery while tapinarof 1% uses a "novel" cream-based vehicle developed by Dermavant Sciences Inc. [103][104][105][106][107] The active ingredient remains the same (3,5-dihydroxy-4-isopropyl-trans-stilbene), isolated from the bacterium Photorhabdus luminescens. 108,109…”
Section: Tapinarofmentioning
confidence: 99%
“…101,102 It was first developed under the name WBI-1001 by Welichem Biotech Inc. in China. 103 Benvitimod 1% (Beijing Wenfeng Tianji Pharma Ltd.) uses a petrolatum-based vehicle for delivery while tapinarof 1% uses a "novel" cream-based vehicle developed by Dermavant Sciences Inc. [103][104][105][106][107] The active ingredient remains the same (3,5-dihydroxy-4-isopropyl-trans-stilbene), isolated from the bacterium Photorhabdus luminescens. 108,109…”
Section: Tapinarofmentioning
confidence: 99%
“…The large-scale preparation of EDITS reported by Gao et al (47) was scaled to the research laboratory and provided sufficient EDITS for this study with the following modifications. The alkylation procedure used by Gao et al on methyl 3,5-dimethoxybenzoate gave the 4-isopropyl derivative (compound 1 in Fig.…”
Section: Liquid Chromatography-electrospray Ionization-tandem Mass Spmentioning
confidence: 99%
“…We first assessed the cytotoxicity of the AmILs against HeLa cervical cancer cells and BEAS-2B lung epithelial cells using the MTS assay. In the MTS assays, and all other assays, the final concentration of DMSO in the assay media was ≤0.1 % as DMSO can affect the permeability of cell membranes at concentrations exceeding 2 %, [47][48][49] and 0.1 % DMSO has been used in previous studies 7,24 assessing the cytotoxicity of AmILs (see ESI † for full details of assay solutions). The AmILs produced dose-dependent reductions in cell viability and the dose-response curves (Fig.…”
Section: Amil Library Design and Effects On Cell Viabilitymentioning
confidence: 99%